FEMASYS INC. - COMMON STOCK

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

11 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

09 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

05 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

03 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

29 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

27 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

08 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

27 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

20 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

17 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

16 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

09 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

07 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

18 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

28 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

21 3 2024 09:00:00 提供 Nasdaq GlobeNewswire

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

20 3 2024 08:15:00 提供 Nasdaq GlobeNewswire

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

13 3 2024 09:00:00 提供 Nasdaq GlobeNewswire

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

06 3 2024 09:00:00 提供 Nasdaq GlobeNewswire

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

28 2 2024 09:00:00 提供 Nasdaq GlobeNewswire